Yeomans Consulting Group Inc. Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Yeomans Consulting Group Inc. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,633 shares of the biopharmaceutical company's stock, valued at approximately $295,000.

A number of other institutional investors have also modified their holdings of GILD. Commerzbank Aktiengesellschaft FI grew its position in shares of Gilead Sciences by 27.4% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 13,326 shares of the biopharmaceutical company's stock valued at $1,493,000 after purchasing an additional 2,863 shares during the last quarter. Kingsview Wealth Management LLC increased its position in shares of Gilead Sciences by 2.9% in the first quarter. Kingsview Wealth Management LLC now owns 43,251 shares of the biopharmaceutical company's stock worth $4,846,000 after acquiring an additional 1,237 shares in the last quarter. Graypoint LLC raised its stake in shares of Gilead Sciences by 8.6% in the 1st quarter. Graypoint LLC now owns 12,156 shares of the biopharmaceutical company's stock valued at $1,362,000 after acquiring an additional 965 shares during the period. Mayflower Financial Advisors LLC lifted its holdings in shares of Gilead Sciences by 7.3% during the 1st quarter. Mayflower Financial Advisors LLC now owns 3,676 shares of the biopharmaceutical company's stock valued at $412,000 after acquiring an additional 249 shares in the last quarter. Finally, Triasima Portfolio Management inc. purchased a new stake in Gilead Sciences during the 1st quarter worth $414,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Cantor Fitzgerald assumed coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Finally, Oppenheimer cut their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $111.38.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the sale, the director owned 8,920 shares of the company's stock, valued at $978,880.80. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the transaction, the chief financial officer directly owned 162,610 shares in the company, valued at approximately $18,054,588.30. This trade represents a 1.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock worth $7,844,775 over the last quarter. 0.27% of the stock is owned by insiders.

Gilead Sciences Price Performance

GILD stock traded down $0.58 during trading on Friday, hitting $108.22. The company had a trading volume of 6,627,889 shares, compared to its average volume of 7,664,711. The company has a fifty day moving average price of $108.58 and a two-hundred day moving average price of $105.06. Gilead Sciences, Inc. has a fifty-two week low of $70.78 and a fifty-two week high of $119.96. The company has a market cap of $134.62 billion, a P/E ratio of 22.78, a P/E/G ratio of 0.71 and a beta of 0.29. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the company posted ($1.32) EPS. The firm's revenue for the quarter was down .3% on a year-over-year basis. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.92%. Gilead Sciences's dividend payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.